Literature DB >> 16723051

Fast-track anaesthesia for laparoscopic cholecystectomy: a prospective, randomized, multicentre, blind comparison of desflurane-remifentanil or sevoflurane-remifentanil.

G Fanelli1, M Berti, A Casati.   

Abstract

BACKGROUND AND
OBJECTIVE: To evaluate the effects of sevoflurane and desflurane in combination with intravenous remifentanil on time for discharge from the postanaesthesia care unit and need for postanaesthesia care unit management after elective laparoscopic cholecystectomy.
METHODS: 231 ASA Grade I-II patients, undergoing elective laparoscopic cholecystectomy in seven University teaching hospital, were randomly allocated to receive a desflurane-remifentanil (n = 105) or sevoflurane-remifentanil (n = 126) anaesthetic. A blinded observer recorded times for emergence and postanaesthesia care unit discharge (achievement of an Aldrete score > or =9), number of patients eligible for postanaesthesia care unit discharge when exiting the operating room and occurrence of adverse events.
RESULTS: Intraoperative cardiovascular stability was similar in the two groups. Emergence, response and extubation occurred earlier after desflurane (5.4 +/- 3 min, 5.5 +/- 3 min and 7.5 +/- 4 min) than sevoflurane (6.6 +/- 3.5 min, 7.2 +/- 4 min and 9.1 +/- 4.2 min) (P = 0.0005, 0.05 and 0.003, respectively). Postanaesthesia care unit bypass was possible in 44 desflurane-remifentanil patients (41%) and 55 sevoflurane- remifenatnil patients (43%) (P = 0.69), while postanaesthesia care unit discharge occurred after 46 min (25th-75th percentiles: 18-40 min) with desflurane and 64 min (25th-75th percentiles: 20-50 min) with sevoflurane (P = 0.04). Postoperative nausea and vomiting was observed in 40 desflurane-remifentanil patients (36%) and 53 sevoflurane-remifentanil patients (42%) (P = 0.42).
CONCLUSIONS: Both the desflurane-remifentanil and sevoflurane-remifentanil combinations provide a similarly adequate intraoperative cardiovascular stability. Emergence and postanaesthesia care unit discharge were faster with desflurane-remifentanil than sevoflurane-remifentanil, but this was not associated with a larger proportion of postanaesthesia care unit bypass, confirming that no clinically relevant differences are present between the two agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723051     DOI: 10.1017/S0265021506000718

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  5 in total

1.  Neuromuscular blockade improves surgical conditions (NISCO).

Authors:  Manfred Blobner; Christiane G Frick; Roland B Stäuble; Hubertus Feussner; Stefan J Schaller; Christoph Unterbuchner; Charlotte Lingg; Martina Geisler; Heidrun Fink
Journal:  Surg Endosc       Date:  2014-08-15       Impact factor: 4.584

2.  Results of introducing a rapid recovery program for total abdominal hysterectomy.

Authors:  Elizabeth Dickson; Peter A Argenta; John A Reichert
Journal:  Gynecol Obstet Invest       Date:  2011-12-07       Impact factor: 2.031

3.  Comparative effect of desflurane and sevoflurane on liver function tests of patients with impaired hepatic function undergoing cholecystectomy: A randomized clinical study.

Authors:  Rabie Soliman; Abdelbadee Yacoub; Mostafa Abdellatif
Journal:  Indian J Anaesth       Date:  2020-05-01

4.  Comparison of sevoflurane and desflurane on effect-site concentration of remifentanil for preventing anesthetic emergence cough in elderly female patients undergoing laparoscopic cholecystectomy.

Authors:  Ha Yeon Kim; Yeo Rae Moon; Suhyun Seok; Bora Kim; Ji Eun Kim; Sook Young Lee
Journal:  Clin Interv Aging       Date:  2018-09-13       Impact factor: 4.458

5.  Total intravenous anesthesia with propofol reduces postoperative nausea and vomiting in patients undergoing robot-assisted laparoscopic radical prostatectomy: a prospective randomized trial.

Authors:  Young-Chul Yoo; Sun-Joon Bai; Ki-Young Lee; Seokyung Shin; Eun Kyeong Choi; Jong Whax Lee
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.